Rezolute: FDA Pivotal Trial Alignment Change Further Bolsters Ersodetug

Rezolute (NASDAQ:RZLT) is progressing ersodetug through two pivotal Phase 3 trials for hyperinsulinism: sunRIZE for congenital HI, with topline data expected in December 2025, and upLIFT for tumor HI, anticipated in Q2 2026. The FDA has aligned with an open-label design for the upLIFT trial, significantly reducing its recruitment to just 16 patients. This development is crucial as ersodetug aims to address a substantial unmet medical need, given that 60% of patients fail to respond to the current first-line treatment for hypoglycemia associated with hyperinsulinism.

Analysis

Rezolute, Inc. (RZLT) is advancing its lead candidate, ersodetug, through two pivotal Phase 3 trials for hyperinsulinism: the sunRIZE trial for congenital HI and the upLIFT trial for tumor HI. A significant positive development is the recent FDA alignment on the upLIFT trial's design, which permits an open-label study and requires only 16 patients. This regulatory agreement substantially reduces clinical execution risk, cost, and timelines for this indication. The drug targets a considerable unmet medical need, highlighted by the fact that 60% of patients with hypoglycemia due to HI fail to respond to the current first-line therapy. Investors have two clear, long-term catalysts on the horizon: topline data from the sunRIZE trial is expected in December 2025, followed by results from the upLIFT trial in the second half of 2026, creating specific inflection points for the company's valuation.

Key Decisions for Investors

• Investors should view the FDA's alignment on the upLIFT trial, particularly the small 16-patient, open-label design, as a significant de-risking event for the clinical pathway of ersodetug.
• The investment thesis is framed by two defined, long-term catalysts, and positions should be managed with an eye toward the sunRIZE trial data readout in December 2025 and the upLIFT trial results in H2 2026.
• Evaluate the potential commercial viability of ersodetug in the context of the high unmet medical need, where an estimated 60% of patients fail the current first-line therapy, suggesting a strong potential for market penetration upon approval.